Medical Marijuana, Inc. announced today that its subsidiary Kannaway® is now available in Russia, Kazakhstan and Kyrgyzstan.
“Our expansion into Russia, Kazakhstan and Kyrgyzstan is an amazing example of Kannaway continuing to blaze a trail in opening up and developing new foreign markets,” said Kannaway CEO Blake Schroeder. “Each new market we enter allows us to offer our products to consumers in need while growing our share of the global $17.4 billion CBD nutraceuticals market.”
Kannaway was the first direct selling company to offer hemp-derived cannabidiol (CBD) products in both the U.S. and Europe. The company currently ships its products to over 30 countries in Europe and throughout the United States. In June 2019, Kannaway announced its expansion into the Asian market.
“Kannaway has pioneered direct selling hemp-derived CBD in the U.S. and Europe and has been rapidly expanding as consumers in new markets are eager to try our products,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We believe that people around the world, no matter their geographic location, should have access to CBD products and we’re here to educate them on why it is so vital to everyday wellness.”
